

Apple Health PDL Drug Class Motions

Anticonvulsants

- ▶ AMPA Glutamate Receptor Antagonists
- ▶ Benzodiazepines - Rescue Agents
- ▶ Misc
- ▶ Neuroactive Steroid - GABA Modulator
- ▶ Succinimides

Anticonvulsants

Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Hudson**
- ▶ **2nd: Barkett**

Antidementia Agents

▶ Antidementia Agents

▶ ~~Anti-Amyloid Antibodies~~

Antidementia Agents

Motion: I move that all products in the drug classes listed on slide 4 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Barkett**
- ▶ **2nd: MacKay**

Atopic Dermatitis Agents : Janus Kinase (JAK) Inhibitors - Oral

- ▶ **Motion:** I move that all products in the Atopic Dermatitis Agents : Janus Kinase (JAK) Inhibitors - Oral class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: Flynn**
- ▶ **2nd: Corsilles**

Cytokine and CAM Antagonists

- ▶ **Motion:** I move that all products in the Cytokine and CAM Antagonists class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.
- ▶ **Motion: MacKay**
- ▶ **2nd: Beste**

AHDPL Classes

▶ Oncology Agents

- ▶ Antiestrogens – Oral
- ▶ Antimetabolites – Oral
- ▶ Autologous Cellular Immunotherapy (CAR-T)
- ▶ Gene Therapies
- ▶ Imidazotetrazines – Oral
- ▶ Mitotic Inhibitors - Oral
- ▶ Nitrosoureas – Oral
- ▶ Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral
- ▶ Selective Retinoid X Receptor Agonists – Oral

AHDPL Classes

▶ Hematopoietic Agents

- ▶ Gaucher Disease
- ▶ Sickle Cell Anemia
- ▶ Sickle Cell Anemia - Selectin Blockers

AHDPL Classes

Motion: I move that all products in the drug classes listed on slides 8 and 9 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in these classes may require prior authorization to determine medical necessity. All non-preferred products require a trial of at least two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: DID NOT REVIEW**
- ▶ **2nd:**